» Articles » PMID: 26579444

Antagonism of Toll-like Receptor 2 Attenuates the Formation and Progression of Abdominal Aortic Aneurysm

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2015 Nov 19
PMID 26579444
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Abdominal aortic aneurysm (AAA) is an inflammatory vascular disorder with high mortality. Accumulating evidence shows that toll-like receptor 2 (TLR2) plays a critical role in the regulation of wound-repairing process after tissue injury. We wondered if TLR2 signaling contributed to the pathogenesis of AAA and that targeting TLR2 would attenuate AAA development and progression. In this study, enhanced expression of TLR2 and its ligands were observed in human AAA tissue. Neutralization of TLR2 protected against AAA development and caused established AAA to regress in mouse models of AAA. In addition, TLR2-deficient mice also failed to develop AAA. The prophylactic and therapeutic effects of blocking TLR2 were accompanied by a significant resolution of inflammation and vascular remodeling, as indicated by the decreased expression or activity of MMP-2/9, α-SMA, inflammatory cytokines, and transcription factors NF-κB, AP-1 and STAT1/3 in AAA tissue. Mechanistically, blocking TLR2 decreased the expression and interaction of TLR2 and several endogenous ligands, which diminished chronic inflammation and vascular remodeling in the vascular tissue of AAA. Our studies indicate that the interactions between TLR2 and its endogenous ligands contribute to the pathogenesis of AAA and that targeting TLR2 offers great potential toward the development of therapeutic agents against AAA.

Citing Articles

Toll-Like Receptor 2 Attenuates the Formation and Progression of Angiotensin II-Induced Abdominal Aortic Aneurysm in ApoE-/- Mice.

Zhang Y, Bagley J, Park H, Cao X, Maganto-Garcia E, Lichtman A J Vasc Res. 2024; 61(6):304-317.

PMID: 39467520 PMC: 11651225. DOI: 10.1159/000541651.


Aortic aneurysms: current pathogenesis and therapeutic targets.

Cho M, Lee M, Park J Exp Mol Med. 2023; 55(12):2519-2530.

PMID: 38036736 PMC: 10766996. DOI: 10.1038/s12276-023-01130-w.


Toll-like Receptors as Pro-Thrombotic Drivers in Viral Infections: A Narrative Review.

Panzer B, Kopp C, Neumayer C, Koppensteiner R, Jozkowicz A, Poledniczek M Cells. 2023; 12(14).

PMID: 37508529 PMC: 10377790. DOI: 10.3390/cells12141865.


Identification of MEDAG and SERPINE1 Related to Hypoxia in Abdominal Aortic Aneurysm Based on Weighted Gene Coexpression Network Analysis.

Teng B, Xie C, Zhao Y, Zeng Q, Zhan F, Feng Y Front Physiol. 2022; 13:926508.

PMID: 35874515 PMC: 9301186. DOI: 10.3389/fphys.2022.926508.


A Review of the Impact of Neutrophils and Neutrophil Extracellular Traps (NETs) on the Development of Aortic Aneurysms in Animal and Human Studies.

Michalska M, Grochowiecki T, Jakimowicz T, Nazarewski S Med Sci Monit. 2021; 27:e935134.

PMID: 34961758 PMC: 8720181. DOI: 10.12659/MSM.935134.


References
1.
Zhang K, Kaufman R . From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008; 454(7203):455-62. PMC: 2727659. DOI: 10.1038/nature07203. View

2.
Pryshchep O, Ma-Krupa W, Younge B, Goronzy J, Weyand C . Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation. 2008; 118(12):1276-84. PMC: 2748975. DOI: 10.1161/CIRCULATIONAHA.108.789172. View

3.
Satoh K, Nigro P, Matoba T, ODell M, Cui Z, Shi X . Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009; 15(6):649-56. PMC: 2704983. DOI: 10.1038/nm.1958. View

4.
Bevilacqua R, Benassi C, Largajolli R, Veronese F . Psychoactive butyrophenones: binding to human and bovine serum albumin. Pharmacol Res Commun. 1979; 11(5):447-54. DOI: 10.1016/s0031-6989(79)80008-9. View

5.
Mosorin M, Juvonen J, Biancari F, Satta J, Surcel H, Leinonen M . Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001; 34(4):606-10. DOI: 10.1067/mva.2001.117891. View